Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients
Open Access
- 17 September 2018
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 105 (3) , 730-737
Abstract
The pharmacokinetic (PK) and clinical implications of combining metformin with rifampicin are relevant to increasing numbers of patients with diabetic tuberculosis (TB) across the world and are yet unclear. We assessed the impact of rifampicin on metformin PKs and its glucose‐lowering effect in patients with diabeticTBby measuring plasma metformin and blood glucose during and afterTBtreatment. Rifampicin increased metformin exposure: plasma area under the plasma concentration‐time curve from time point 0 to the end of the dosing interval (AUC0–τ) and peak plasma concentration (Cmax) geometric mean ratio (GMR; during vs. afterTBtreatment) were 1.28 (90% confidence interval (CI) 1.13–1.44) and 1.19 (90%CI1.02–1.38;n = 22). The metformin glucose‐lowering efficacy did not change (Δglucose − Cmax;P = 0.890;n = 18). Thus, we conclude that additional glucose monitoring in this population is not warranted. Finally, 57% of patients on metformin and rifampicin, and 38% of patients on metformin alone experienced gastrointestinal adverse effects. Considering this observation, we advise patients to take metformin and rifampicin with food and preferably separated in time. Clinicians could consider metoclopramide if gastrointestinal adverse effects occur.Keywords
Funding Information
- Seventh Framework Programme (305279.)
This publication has 40 references indexed in Scilit:
- Disease, Drug Metabolism, and Transporter InteractionsPharmaceutical Research, 2013
- Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin CNew England Journal of Medicine, 2012
- Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer PatientsClinical Cancer Research, 2012
- Nuclear receptor PXR, transcriptional circuits and metabolic relevanceBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- The impact of diabetes on tuberculosis treatment outcomes: A systematic reviewBMC Medicine, 2011
- Expression of Organic Cation Transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) Is Affected by Genetic Factors and Cholestasis in Human Liver†Hepatology, 2009
- Diabetes Mellitus Increases the Risk of Active Tuberculosis: A Systematic Review of 13 Observational StudiesPLOS Medicine, 2008
- Metformin Transport by a Newly Cloned Proton-Stimulated Organic Cation Transporter (Plasma Membrane Monoamine Transporter) Expressed in Human IntestineDrug Metabolism and Disposition, 2007
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003
- Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin AntibacterialsClinical Pharmacokinetics, 2001